To determine the role of p38 MAPK inhibition in cisplatin-surviving tumor cells, differences between cisplatin alone (control) and cisplatin plus SB202190 treated cells as well as TGF-beta-1-stimulated before cisplatin and SB202190-treated after cisplatin was evaluated by MTT assay and FACS analysis. Here, TGFB1 is linked to neoplasm.